

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

February 2, 2012
Date of Report (date of earliest event reported)

CUTERA™

Cutera, Inc.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or
organization)

000-50644
(Commission File Number)

77-0492262
(I.R.S. Employer Identification Number)

3240 Bayshore Blvd.
Brisbane, California 94005
(Address of principal executive offices)

(415) 657-5500
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On February 3, 2012, Cutera, Inc. issued a press release announcing the completion of the acquisition of certain assets related to a line of business from IRIDEX Corporation. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.**(d) Exhibits.**

Exhibit No.	Description
<u>99.1</u>	Press Release of Cutera, Inc. dated as of February 3, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUTERA, INC.

Date: February 3, 2012

/s/ RONALD J. SANTILLI
Ronald J. Santilli
EVP, Finance and Administration and Chief Financial Officer



For Immediate Release

For more information please contact:

Cutera, Inc.

Ron Santilli, Chief Financial Officer
Phone: (888) 4-CUTERA or (415) 657-5500

Cutera Investor Relations

John Mills
Integrated Corporate Relations, Inc.
Phone: (310) 954-1105
john.mills@icrinc.com

Cutera Closes the Acquisition of IRIDEX Aesthetic Business Unit

Brisbane, Calif. — February 03, 2012—Cutera, Inc. (NASDAQ: CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, today announced that it has closed the previously announced asset purchase of IRIDEX' global aesthetic business for \$5.1 million in cash.

"We are pleased to announce the closing of this acquisition, as it advances Cutera's presence among core physicians worldwide, and positions us as a leader in the vascular aesthetic market," said Kevin Connors, president and chief executive officer of Cutera. "Now, with an expanded customer base, Cutera will be able to leverage cross-selling opportunities to our expanded installed base. We remain committed to providing the highest quality of customer service worldwide."

Cutera's newest product offering is the portable VariLite™ dual wavelength (532 nm and 940 nm) system, a solid-state laser that offers the clinical versatility to treat vascular lesions, pigmentation and cutaneous lesions, in a convenient and compact package. The addition of the VariLite system to Cutera's existing premium vascular lineup, including the state-of-the-art Excel V™ laser and Xeo™ vascular applications, enables Cutera to reach a wider range of physicians at multiple price points.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995: Specifically, statements concerning the features, effectiveness, treatable conditions, and the potential market size for Cutera's new product, are forward-looking statements within the meaning of the Safe Harbor. Such forward-looking statements are subject to risks and uncertainties and may be affected by various factors that may cause actual results to differ materially from those in the forward-looking statements and those other factors described in the section entitled, "Risk Factors", in Cutera's most recent Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2011. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
